Empagliflozin (Jardiance®). HTA ID: 24042

Assessment Status Rapid Review Complete
HTA ID 24042
Drug Empagliflozin
Brand Jardiance®
Indication Empagliflozin is indicated in adults for the treatment of chronic kidney disease.
Assessment Process
Rapid review commissioned 09/10/2024
Rapid review completed 22/11/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that empagliflozin be considered for reimbursement for this indication*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement. April 2025